Pathology & Oncology Research

, Volume 17, Issue 3, pp 779–784 | Cite as

Spontaneous Remission in Localized Diffuse Large B-cell Lymphoma

  • László TamásEmail author
  • Eszter Sári
  • Gábor Répássy
  • Péter Szabó
  • Enikő Bagdi
  • László Krenács
  • Judit Demeter
Case Report


Diffuse large B-cell lymphoma (DLBCL) is an aggressive neoplastic disease of the lymphatic system, the activated B-cell type of this disease is likely to have a substantially worse prognosis. In this study, we report the favorable outcome of the activated B-cell type of DLBCL, though untreated, 7 years after diagnosis. In 2003, DLBCL localized to the root of tongue was found in the patient complaining of dysphonia and a pharyngeal globus perception but the patient did not agree to get any active hematological treatment. During the following years, the patient did not have any complaints. At the otorhinolaryngological control examination, in 2010, she was complaint-free, had normal laboratory parameters. Moreover a PET-CT scan did not reveal metabolic activity relating to malignancy. The extraordinary disease process can be explained by the spontaneous regression of the activated B-cell type DLBCL. Spontaneous regression of oral lymphoma has been published only exceptionally. To our knowledge, no report of spontaneous regression of activated B-cell type DLBLC has been reported.


Diffuse large B-cell lymphoma Spontaneous remission Activated B-cell type DLBLC Root of tongue Untreated lymphoma 



Diffuse large B-cell lymphoma


International Prognostic Index


Age adjusted International Prognostic Index


Germinal center-B-cell type


Activated B-cell type

Bcl 2

B-cell lymphoma 2


Multiple myeloma oncogene 1

Cytokeratin A1-A3

Pankeratin monoclonal antibody


Human Germinal Center Associated Lymphoma Protein




EBV-Latent membrane protein 1


complete blood count…


Lactate dehidrogenase




Computer Tomography


Positron Emission Tomography




Non-Hodgkin’s lymphoma


Interleukin −4


  1. 1.
    Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRefGoogle Scholar
  2. 2.
    Chang CC, McClintock S, Ronald P et al (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464–470PubMedCrossRefGoogle Scholar
  3. 3.
    Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRefGoogle Scholar
  4. 4.
    Papac RJ (1999) Spontaneous regression of cancer. Cancer Treatment Reviews 22:395–423CrossRefGoogle Scholar
  5. 5.
    Sengupta N, MacFie TS, MacDonald TT et al (2010) Cancer immunoediting and “spontaneous” tumor regression. Path Res and Pract 206:1–8CrossRefGoogle Scholar
  6. 6.
    Fujimoto K, Endo T, Nishio M et al (2009) Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier. Int J Hematol 90:601–604PubMedCrossRefGoogle Scholar
  7. 7.
    Drobyski WR, Qazi (1989) Spontaneous regression in non-Hodgkin’s lymphoma: clinical and pathogenic considerations. Am J Hem 31:138–141CrossRefGoogle Scholar
  8. 8.
    Gattiker HH, Wiltshaw E, Galton DAG (1980) Spontaneous regression in non-Hodgkin ’s lymphoma. Cancer 45:2627–2632PubMedCrossRefGoogle Scholar
  9. 9.
    Krikorian JG, Carol S, Cooney DP et al (1980) Spontaneous regression of non-Hodgkin’s Lymphoma: a report of nine cases. Cancer 46:2093–2099PubMedCrossRefGoogle Scholar
  10. 10.
    Abe R, Ogawa K, Maruyama Y et al (2007) Spontaneous regression of diffuse large B-cell lymphoma harbouring epstein-barr virus: a case report and review of the literature. J Clin Exp Hematopathol 47:23–26CrossRefGoogle Scholar
  11. 11.
    Evans LS, Hancock B (2003) Non-Hodgkin lymphoma. The Lancet Vol 362:139–146CrossRefGoogle Scholar
  12. 12.
    Daly RM, Healy CM, Toner ME et al (2008) Spontaneous regression of non-Hodgkin’s lymphoma int he oral cavity after incisional biopsy. Br J Or Maxillofac Surg 46:223–225CrossRefGoogle Scholar
  13. 13.
    Savarrio L, Gibosn J, Dunlop DJ et al (1999) Spontaneous regression of an anaplastic large cell lymphoma int he oral cavity: first reported case and review of the literature. Or Onc 35:609–613CrossRefGoogle Scholar
  14. 14.
    Koga M, Kusukawa J, Havabuchi N (2003) Spontaneous regression of extranodal malignant lymphoma occurred int he gingiva. Or Onc 39:323–324CrossRefGoogle Scholar
  15. 15.
    Iqbal J, Greiner TC, Patel K et al (2009) Gene expression profiling in lymphoma diagnosis and management. Best Pract & Res Clin Haem 22:191–210CrossRefGoogle Scholar
  16. 16.
    Camilleri-Broet S, Criniére E, Broet P et al (2006) A uniform activated B-cell-like immunophenotpye might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196PubMedCrossRefGoogle Scholar
  17. 17.
    Lu X, Nechushtan H, Ding F et al (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell like and activated B-cell –like diffuse large-cell lymphomas. Blood 105(7):2924–2932PubMedCrossRefGoogle Scholar
  18. 18.
    Barrans SL, Carter I, Owen RG et al (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136–1143PubMedCrossRefGoogle Scholar
  19. 19.
    Armitage JO (2008) Is lymphoma occuring int he elderly the same disease? Leuk Lymphoma 49:14–6PubMedCrossRefGoogle Scholar
  20. 20.
    Gutiérrez A, Mestre F, Pérez-Manga G, Rodríguez J (2010) Diffuse large B-cell lymphoma in the older. Crit Rev Oncol Hematol Mar 18. [Epub ahead of print] doi: 10.1016/j.critrevonc.2010.02.009
  21. 21.
    Liu Y-H, Xu FP, Zhuang HG et al (2008) Clinicopathologic significance of immunphenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Path 39:875–884PubMedCrossRefGoogle Scholar
  22. 22.
    Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:5103–10PubMedCrossRefGoogle Scholar
  23. 23.
    Miller TP, Unger JM, Spier CM et al (2004) Effect of adding rituximab to three cycles of CHOP plus involved –field radiotherapy for limited –stage agressive diffuse B-cell lymphoma ( SWOG-0014). Blood 104:48aGoogle Scholar
  24. 24.
    Persky DO, Unger JM, Spier CM et al (2008) Phase II study of rituximab plus three cycles of CHOP and involved –field radiotherapy for patients with limited-stage agressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26(14):2258–2263PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2011

Authors and Affiliations

  • László Tamás
    • 1
    Email author
  • Eszter Sári
    • 2
  • Gábor Répássy
    • 3
  • Péter Szabó
    • 4
  • Enikő Bagdi
    • 5
  • László Krenács
    • 5
  • Judit Demeter
    • 2
  1. 1.Department of Oto-Rhino-Laryngology, Head and Neck SurgeryJahn Ferenc HospitalBudapestHungary
  2. 2.1st Department of Internal Medicine—Division of HematologySemmelweis UniversityBudapestHungary
  3. 3.Department of Oto-Rhino-Laryngology, Head and Neck SurgerySemmelweis UniversityBudapestHungary
  4. 4.PET-CT Medical Diagnostic Ltd.BudapestHungary
  5. 5.Laboratory of Tumor Pathology and Molecular Diagnostics SzegedSzegedHungary

Personalised recommendations